Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.51 |
| ▸ | OGG1 | O15527 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204553 | 0.83 | HTR1B (0.67) | HTR1BKCNA3ALDH1A1HPGDTDP1 | |
| SCHEMBL5289923 | 0.82 | HTR1B (0.77) | HTR1BKDM4EKCNA3ALDH1A1HPGD | |
| SCHEMBL16902842 | 0.82 | HTR1B (0.64) | HTR1BKDM4EKCNA3ALDH1A1HPGD | |
| SCHEMBL2207985 | 0.82 | HTR1B (0.68) | HTR1BKCNA3TDP1HTR1DSLC6A4 | |
| SCHEMBL1681047 | 0.80 | KCNA3 (0.69) | HTR1BKCNA3TDP1HTR1DSLC6A4 | |
| SCHEMBL6675778 | 0.80 | HTR1B (0.62) | HTR1BKDM4EKCNA3ALDH1A1HPGD | |
| SCHEMBL2177350 | 0.80 | HTR1B (0.78) | HTR1BKCNA3TDP1HTR1DSLC6A4 | |
| SCHEMBL9770352 | 0.80 | KCNA3 (0.81) | HTR1BKCNA3TDP1HTR1DSLC6A4 | |
| SCHEMBL30499047 | 0.80 | KDM4E (0.68) | HTR1BKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL9329851 | 0.80 | KDM4E (0.68) | HTR1BKDM4EALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113461553-A | Synthesis method of dapoxetine and dapoxetine hydrochloride | 上海科利生物医药有限公司 | 2021-10-01 | — | — | CN | claimed |
| CN-113024365-B | Industrial production method of benzo [ c ] phenanthrene-5-trifluoromethanesulfonate | 西安瑞联新材料股份有限公司 | 2023-02-10 | — | — | CN | disclosed |
| CN-113461553-A | Synthesis method of dapoxetine and dapoxetine hydrochloride | 上海科利生物医药有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-113461553-A | Synthesis method of dapoxetine and dapoxetine hydrochloride | 上海科利生物医药有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-113024365-A | Industrial production method of benzo [ c ] phenanthrene-5-trifluoromethanesulfonate | 西安瑞联新材料股份有限公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20030032779-A1 | Estrogen receptor ligands | OHMAN LARS (SE) | 2003-02-13 | — | — | US | disclosed |
| WO-1997015566-A1 | NOVEL OLIGOMERS, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE | GEORGHIOU PARIS E (CA) | 1997-05-01 | — | — | WO | disclosed |
| US-4087403-A | Polyphosphinate flame retardants | MONSANTO COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032779-A1 | Estrogen receptor ligands | ESR1, ESRRB, GPER1 | HTR1B 1792/4885KDM4E 3197/4885KCNA3 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.